ES2149206T3 - Purificacion de proteinas. - Google Patents

Purificacion de proteinas.

Info

Publication number
ES2149206T3
ES2149206T3 ES93908538T ES93908538T ES2149206T3 ES 2149206 T3 ES2149206 T3 ES 2149206T3 ES 93908538 T ES93908538 T ES 93908538T ES 93908538 T ES93908538 T ES 93908538T ES 2149206 T3 ES2149206 T3 ES 2149206T3
Authority
ES
Spain
Prior art keywords
protein purification
purification
application
invention refers
receptor proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93908538T
Other languages
English (en)
Inventor
Gail Folena-Wasserman
John H O'grady
Thomas M Smith
John Lifter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celldex Therapeutics Inc
Original Assignee
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Immunotherapeutics Inc filed Critical Avant Immunotherapeutics Inc
Application granted granted Critical
Publication of ES2149206T3 publication Critical patent/ES2149206T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ESTA INVENCION SE REFIERE A LA APLICACION DE UNA CROMATOGRAFIA DE COMBINACION A LA PURIFICACION DE PROTEINAS RECEPTORAS COMPLEMENTARIAS.
ES93908538T 1992-03-24 1993-03-24 Purificacion de proteinas. Expired - Lifetime ES2149206T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/857,022 US5252216A (en) 1992-03-24 1992-03-24 Protein purification

Publications (1)

Publication Number Publication Date
ES2149206T3 true ES2149206T3 (es) 2000-11-01

Family

ID=25324998

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93908538T Expired - Lifetime ES2149206T3 (es) 1992-03-24 1993-03-24 Purificacion de proteinas.

Country Status (19)

Country Link
US (1) US5252216A (es)
EP (1) EP0643608B1 (es)
JP (1) JP3335629B2 (es)
KR (1) KR100241172B1 (es)
AT (1) ATE193839T1 (es)
AU (1) AU659936B2 (es)
CA (1) CA2132533C (es)
DE (1) DE69328864T2 (es)
DK (1) DK0643608T3 (es)
ES (1) ES2149206T3 (es)
FI (1) FI109202B (es)
GR (1) GR3034332T3 (es)
MX (1) MX9301655A (es)
NO (1) NO310855B1 (es)
NZ (1) NZ251601A (es)
PT (1) PT643608E (es)
TW (1) TW321651B (es)
WO (1) WO1993018835A1 (es)
ZA (1) ZA932015B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
DE4331358A1 (de) * 1992-10-12 1994-04-14 Braun Melsungen Ag Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten
CN1130353A (zh) * 1993-07-09 1996-09-04 史密丝克莱恩比彻姆公司 蛋白质的纯化
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
DE19549420A1 (de) * 1995-04-27 1997-09-18 Braun Melsungen Ag Verfahren zur simultanen extrakorporalen Elimination von Tumor-Nekrose Faktor alpha (TNF alpha) und bakteriellen Lipopolysacchariden (LPS) aus Vollblut oder/und Blutplasma
DE69627333T2 (de) * 1995-06-26 2004-02-12 PerSeptive Biosystems, Inc., Framingham Automatisierte, kontinuierliche mehrdimensionale hochgeschwindigkeitsmolekularselektion und -analyse
EP1300679A3 (en) * 1995-06-26 2004-04-14 Perseptive Biosystems, Inc. Molecular selection and analysis
GB9515196D0 (en) * 1995-07-25 1995-09-20 Matthey Rustenburg Refines Interseparation of platignum group metals
CA2294749C (en) * 1997-06-27 2007-01-02 Life Technologies, Inc. One step device and process for concentration and purification of biological molecules
US5993653C1 (en) * 1997-08-11 2001-11-06 Phenomenex Composition and column used in hplc
US6869796B2 (en) * 1997-08-26 2005-03-22 Avaris Ab Method of introducing organic molecules into target cells
US20070122904A1 (en) * 2000-09-29 2007-05-31 Unisearch Limited Method and apparatus for culturing cells
US6855263B2 (en) * 2002-07-23 2005-02-15 Nuvue Technologies, Inc. Rapid process for purification and concentration of plasmin
DE10255508A1 (de) * 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
US6913695B2 (en) * 2003-07-08 2005-07-05 Bayer Healthcare Llc Sanitization of chromatographic media
WO2005012349A2 (en) * 2003-08-01 2005-02-10 Lorantis Limited Chromatographic process for the purification of notch ligands
US7329353B2 (en) * 2004-01-23 2008-02-12 Amgen Inc. LC/MS method of analyzing high molecular weight proteins
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
PL1787126T3 (pl) * 2004-07-20 2010-03-31 Symphogen As Sposób charakteryzowania poliklonalnej linii komórkowej
WO2006011580A1 (ja) * 2004-07-27 2006-02-02 Genomidea, Inc. ウイルスエンベロープの精製方法
EP1789454B1 (en) * 2004-08-12 2017-07-05 Lipoxen Technologies Limited Fractionation of charged polysaccharide
EP1738763A1 (en) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
WO2007053235A1 (en) * 2005-11-04 2007-05-10 Sachem, Inc. Cation-exchange displacement chromatography process and cationic organic compounds for use as displacer compounds in cation-exchange displacement chromatography process
EP2596807B1 (en) 2006-03-08 2015-12-16 Archemix LLC Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
WO2010101865A1 (en) 2009-03-02 2010-09-10 Zymo Research Corporation Universal column
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
CN103237557A (zh) 2010-09-15 2013-08-07 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
EP2632476B1 (en) 2010-10-27 2017-06-14 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
KR20250026267A (ko) * 2022-06-17 2025-02-25 씨에스엘 이노베이션 피티와이 엘티디 가용성 보체 수용체 및 이의 변이체의 정제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2319495C2 (de) * 1973-04-17 1985-01-10 Yeda Research And Development Co., Ltd., Rehovot Verfahren zum selektiven, reversiblen Binden von Biomolekülen an ein Adsorbens in einer chromatographischen Säule
US4000098A (en) * 1974-08-16 1976-12-28 Palo Alto Medical Research Foundation Separation of proteins by hydrophobic adsorption
DE3149360A1 (de) * 1981-12-12 1983-06-16 Biotest-Serum-Institut Gmbh, 6000 Frankfurt "verfahren zur reinigung und/oder phytohaemagglutinin-abtrennung von human-interleukin-2"
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
AU597924B2 (en) * 1985-12-11 1990-06-14 Natinco Nv Solubilization of protein aggregates
US4770781A (en) * 1986-03-03 1988-09-13 Merck & Co., Inc. Purification of human interleukin-1 species
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
AU609824B2 (en) * 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
US4981799A (en) * 1987-08-21 1991-01-01 Takeda Chemical Industries, Ltd. Acylamino acid racemase, production and use thereof
US4765903A (en) * 1987-10-06 1988-08-23 Interferon Sciences, Inc. Purification of monomeric interferon
US5159063A (en) * 1989-02-02 1992-10-27 The United States Of America As Represented By The Department Of Health And Human Services Isolation and characterization of a 120 kda glycoprotein plasma
US5030352A (en) * 1990-01-25 1991-07-09 Purdue Research Foundation Coated media for chromatography

Also Published As

Publication number Publication date
AU3932493A (en) 1993-10-21
FI944412L (fi) 1994-09-23
EP0643608B1 (en) 2000-06-14
MX9301655A (es) 1994-03-31
NO310855B1 (no) 2001-09-10
ATE193839T1 (de) 2000-06-15
TW321651B (es) 1997-12-01
DE69328864T2 (de) 2000-12-14
CA2132533C (en) 2004-01-13
FI109202B (fi) 2002-06-14
GR3034332T3 (en) 2000-12-29
US5252216A (en) 1993-10-12
WO1993018835A1 (en) 1993-09-30
AU659936B2 (en) 1995-06-01
DE69328864D1 (de) 2000-07-20
NZ251601A (en) 1997-03-24
KR950700779A (ko) 1995-02-20
PT643608E (pt) 2000-11-30
ZA932015B (en) 1994-09-21
CA2132533A1 (en) 1993-09-30
FI944412A0 (fi) 1994-09-23
JP3335629B2 (ja) 2002-10-21
NO943546D0 (no) 1994-09-23
JPH07505469A (ja) 1995-06-15
DK0643608T3 (da) 2000-10-02
KR100241172B1 (ko) 2000-02-01
EP0643608A4 (en) 1997-11-26
NO943546L (no) 1994-11-23
EP0643608A1 (en) 1995-03-22

Similar Documents

Publication Publication Date Title
MX9301655A (es) Purificacion de proteina.
BR9507100A (pt) Purificação de anticorpos
HN1997000146A (es) Derivados de pirimidina biciclica condensada
NO994998L (no) Fusjonsproteiner
HN1997000166A (es) 1-arilpirazoles plaguicidas
HN1997000126A (es) Derivados de indazol
HN1998000132A (es) Combinaciones terapeuticas
HN1997000023A (es) Derivados de lactama
HN1997000090A (es) Compuestos de piridilpirrol
ES2076999T3 (es) Peptidos anticoagulantes radiomarcados.
ES2193197T3 (es) Craquizacion catalitica com mcm-49.
MX9302614A (es) Receptor de glutamato metabotropico humano y compuestos de dna relacionados.
ITRM920658A0 (it) Procedimento per la purificazione della proteina endotelina
NO991175L (no) Anvendelse av proteiner som midler mot autoimmune sykdommer
HN1998000102A (es) Composiciones solubilizadas de sertralina
EP0832126A4 (en) G-PROTEIN RECEPTOR HTNAD29
ES2094228T3 (es) Peptidos anticoagulantes.
FI946031L (fi) Kringleä sisältävien proteiinien puhdistus ja etenkin t-PA:n
HN1998000078A (es) Sal tartrato de un dipeptido sustituido.
HN1997000354A (es) Nucleosidas terapeuticas
HN1998000014A (es) Metodo de purificacion de 1,3,5, trii sopropilbenceno
MX9603809A (es) Preparado combinado farmaceutico con ketoprofeno.
ITMI931263A0 (it) Intermedi per la preparazione di peptidi retro-inversi
HN1996000127A (es) Encendedor

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 643608

Country of ref document: ES